English 
搜索
Hebei Lansheng Biotech Co., Ltd. ShangHai Yuelian Biotech Co., Ltd.

Dow, DuPont issue statement on EC reviewqrcode

Aug. 24, 2016

Favorites Print
Forward
Aug. 24, 2016
DuPont and the Dow Chemical Company confirmed that the European Commission (EC) has initiated a Phase II review for the proposed merger of equals transaction of the two companies. As stated previously, the companies expected a thorough review and are working closely with relevant regulators, including the EC. The companies continue to believe the merger is pro-competitive and good for customers and consumers. 
 
The Phase II review is a common next step in the review process for a transaction of this size and scope under EU Merger Regulation. Under this regulation, Phase II generally provides the Commission with 90 working days to review the pending transaction. Dow and DuPont will continue to work constructively with the Commission to address their concerns and to obtain clearance for the merger, which we are confident will be achieved. 
 
On June 22, DuPont and Dow began the formal process to obtain merger approval from the European Commission by submitting the required filing to obtain regulatory clearance in connection with the proposed merger of equals. Dow and DuPont continue to expect the transaction to close by year-end 2016, subject to satisfaction of customary closing conditions, including receipt of regulatory approvals. 
 

0/1200

More from AgroNewsChange

Hot Topic More

Subscribe Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

0/1200

 

NEWSLETTER

Subscribe AgroNews Daily Alert to send news related to your mailbox